product name Nutlin-3b
References: Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. Mol Cancer Ther. 2006 Feb;5(2):411-7.
581.49
Formula
C30H30Cl2N4O4
CAS No.
675576-97-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (172.0 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 100 mg/mL (172.0 mM)
Solubility (In vivo)
Chemical Name
2-Piperazinone, 4-[[(4R,5S)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-
other peoduct :
| Nutlin-3a induces the expression of MDM2 and p21 (but not p53) only in cells with wild-type p53. Nutlin-3b has no effect regardless of the p53 status of the cells. Only the active enantiomer Nutlin-3a shows a potent antiproliferative activity and clear separation of potency between the cells harboring wild-type p53 and those harboring mutant p53. The potency of Nutlin-3b is much lower in the wild-type p53 cells and nearly identical to the potency of Nutlin-3a against the mutant p53 cells. After 48 hours of exposure to the Nutlin-3a, 45% of the cell population became TUNEL positive, but cells treated with the Nutlin-3b are indistinguishable from the untreated controls. | |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | [1] Vassilev LT, et al. Science, 2004, 303(5659), 844-848. |
